Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP10 | P09238 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | MMP16 | P51512 | 1/20 | 0.38 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.36 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1168360 | 0.89 | NR1H4 (0.45) | ALDH1A1RAB9AL3MBTL1VNN1NPC1 | |
| SCHEMBL1168181 | 0.80 | KMT2A (0.56) | ALDH1A1RAB9AGCK | |
| SCHEMBL1169210 | 0.79 | NR1H4 (0.50) | RAB9AVNN1NPC1OPRK1KCNH2 | |
| SCHEMBL25120310 | 0.77 | RAB9A (0.48) | ALDH1A1RAB9AGCKNPC1 | |
| SCHEMBL25120247 | 0.73 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1 | |
| SCHEMBL12421153 | 0.72 | ALDH1A1 (0.56) | ALDH1A1RAB9AL3MBTL1NPC1 | |
| SCHEMBL13096994 | 0.72 | CHRNB4 (0.48) | RAB9ANPC1 | |
| SCHEMBL12877016 | 0.71 | RAB9A (0.49) | ALDH1A1RAB9AL3MBTL1NPC1 | |
| SCHEMBL12509074 | 0.69 | EPHX2 (0.51) | ALDH1A1 | |
| SCHEMBL3103247 | 0.69 | SIGMAR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039853-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-02-17 | — | — | US | claimed |
| EP-2150526-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2010-02-10 | — | — | EP | claimed |
| WO-2008101914-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (GB) | 2008-08-28 | — | — | WO | claimed |
| EP-2150526-B1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2150526-B1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-8907096-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-8907096-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-8907096-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140315905-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140315905-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140315905-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC | 2014-10-23 | — | — | US | disclosed |
| US-20130231341-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8383820-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383820-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383820-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110039853-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-02-17 | — | — | US | disclosed |
| US-20110039853-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-02-17 | — | — | US | disclosed |
| EP-2150526-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008101914-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (GB) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101914-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (GB) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039853-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | ALDH1A1 116/4885RAB9A 2384/4885GCK 1604/4885 |
| US-20130231341-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | ALDH1A1 116/4885RAB9A 2384/4885GCK 1604/4885 |
| US-20140315905-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | ALDH1A1 116/4885RAB9A 2384/4885GCK 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.